Board of Director
Owen Hughes is the current CEO of XOMA Royalty, a biotech royalty aggregator company. He has also been the CEO of Sail Bio, Inc., a private biotechnology company focused on addressing toxic proteinopathies.
Previously, Owen was the CEO and co-founder of Cullinan Oncology, Inc., a publicly traded oncology company, from September 2017 to October 2021. Before that, he served as the Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, Inc., a biotechnology company focused on type II diabetes, where he was responsible for financing, mergers and acquisitions (M&A), business development, and operations.
Owen spent 16 years on Wall Street in various capacities, including as a Director at Brookside Capital, an operating division of Bain Capital, managing public and private healthcare investments, and as a Senior Portfolio Manager at Pyramis Global Advisors, a Fidelity Investments company.
He has extensive experience serving on corporate boards. Owen has been a member of the Board of Directors of Ikena Oncology, Inc., a publicly traded oncology company, since December 2022, and C4 Therapeutics since December 2023. He previously served on the Board of Radius Health, Inc., from April 2013 to August 2022, until its sale to Gurnet Point Capital and Patient Square Capital; Translate Bio, Inc., from July 2016 until its acquisition by Sanofi in September 2021; and FS Development Corp. II, a special purpose acquisition company sponsored by Foresite Capital, from February 2021 to December 2021.
Owen holds a B.A. in History from Dartmouth College and brings significant experience with biopharmaceutical companies, combining operational expertise with extensive leadership in the biotechnology and healthcare sectors.
